NEW YORK (GenomeWeb News) – Danish drug discovery firm Nuevolution today said it will employ its screening technology as part of a consortium to identify and develop small molecule drugs against epigenetic disorders.
Nuevolution, based in Copenhagen, Denmark, joins the consortium that also includes EpiTherapeutics, ExpreS2ion Biotechnologies, and the research group of Kristian Helin at the Biotech Research & Innovation Centre at the University of Copenhagen.
For the collaboration, Nuevolution will use its Chemetics high-throughput and fragment-based screening technology to screen hundreds of millions of small molecules, it said in a statement. The Chemetics platform enables rapid synthesis and DNA tagging of hundreds of millions of chemically diverse drug-like small molecule compounds, said Nuevolution.
The other members will provide biology and disease expertise.
The DKK24 million ($4.5 million) project is being funded by the Danish High Technology Fund.